| Schedule of Reportable Segments |
The following table presents information
about the Company’s reportable segments for the three months ended December 31, 2025 and 2024:
| | |
Three Months Ended December 31, | |
| | |
2025 | | |
2024 | |
| | |
Pharma | | |
Commercial | | |
Total | | |
Pharma | | |
Commercial | | |
Total | |
| | |
$ | | |
$ | | |
$ | | |
$ | | |
$ | | |
$ | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| Sales | |
| - | | |
| 820,188 | | |
| 820,188 | | |
| - | | |
| 1,111,707 | | |
| 1,111,707 | |
| Cost of sales | |
| - | | |
| (635,994 | ) | |
| (635,994 | ) | |
| - | | |
| (650,813 | ) | |
| (650,813 | ) |
| Research and development | |
| (624,644 | ) | |
| (5,992 | ) | |
| (630,636 | ) | |
| (890,513 | ) | |
| (4,663 | ) | |
| (895,176 | ) |
| General and Administrative | |
| (1,323,249 | ) | |
| (297,846 | ) | |
| (1,621,095 | ) | |
| (1,358,877 | ) | |
| (359,897 | ) | |
| (1,718,774 | ) |
| Amortization and depreciation | |
| (52,602 | ) | |
| (599 | ) | |
| (53,201 | ) | |
| (52,603 | ) | |
| (599 | ) | |
| (53,202 | ) |
| Foreign exchange gain (loss) | |
| 18,136 | | |
| - | | |
| 18,136 | | |
| (47,753 | ) | |
| - | | |
| (47,753 | ) |
| Interest and other income | |
| 74,379 | | |
| - | | |
| 74,379 | | |
| 30,536 | | |
| - | | |
| 30,536 | |
| Finance expense | |
| - | | |
| - | | |
| - | | |
| (351,549 | ) | |
| - | | |
| (351,549 | ) |
| Net Income (Loss) | |
| (1,907,980 | ) | |
| (120,243 | ) | |
| (2,028,223 | ) | |
| (2,670,759 | ) | |
| 95,735 | | |
| (2,575,024 | ) |
The following table presents information
about the Company’s reportable segments for the six months ended December 31, 2025 and 2024:
| | |
Six Months Ended December 31, | |
| | |
2025 | | |
2024 | |
| | |
Pharma | | |
Commercial | | |
Total | | |
Pharma | | |
Commercial | | |
Total | |
| | |
$ | | |
$ | | |
$ | | |
$ | | |
$ | | |
$ | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| Sales | |
| - | | |
| 1,940,309 | | |
| 1,940,309 | | |
| - | | |
| 2,376,345 | | |
| 2,376,345 | |
| Cost of sales | |
| - | | |
| (1,352,956 | ) | |
| (1,352,956 | ) | |
| - | | |
| (1,422,038 | ) | |
| (1,422,038 | ) |
| Research and development | |
| (1,200,102 | ) | |
| (12,146 | ) | |
| (1,212,248 | ) | |
| (1,582,352 | ) | |
| (12,969 | ) | |
| (1,595,321 | ) |
| General and Administrative | |
| (2,562,307 | ) | |
| (590,803 | ) | |
| (3,153,110 | ) | |
| (2,668,093 | ) | |
| (543,642 | ) | |
| (3,211,735 | ) |
| Amortization and depreciation | |
| (105,205 | ) | |
| (1,198 | ) | |
| (106,403 | ) | |
| (106,583 | ) | |
| (1,198 | ) | |
| (107,781 | ) |
| Foreign exchange gain (loss) | |
| (38,858 | ) | |
| - | | |
| (38,858 | ) | |
| (28,443 | ) | |
| - | | |
| (28,443 | ) |
| Interest and other income | |
| 168,144 | | |
| - | | |
| 168,144 | | |
| 87,630 | | |
| - | | |
| 87,630 | |
| Finance expense | |
| - | | |
| - | | |
| - | | |
| (351,549 | ) | |
| - | | |
| (351,549 | ) |
| Net Income (Loss) | |
| (3,738,328 | ) | |
| (16,794 | ) | |
| (3,755,122 | ) | |
| (4,649,390 | ) | |
| 396,498 | | |
| (4,252,892 | ) |
| Cash and Cash Equivalents | |
| 6,739,445 | | |
| 215,389 | | |
| 6,954,834 | | |
| 4,346,193 | | |
| 1,236,846 | | |
| 5,583,039 | |
|